Drug intelligence / Profile preview

temsirolimus + trebananib

Development stage: Unknown
Lead developer: Pfizer
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous

Overview

The combination of temsirolimus and trebananib is an investigational drug combination that has been studied in clinical trials for advanced solid tumors. This combination targets both the ANG-Tie2 pathway (via trebananib) and the mTOR pathway (via temsirolimus). Trebananib (also known as AMG 386) is an inhibitor of ANG1/2-Tie2 interaction that may stop tumor growth by blocking blood flow to tumors. Temsirolimus is an mTOR inhibitor that may stop the growth of tumor cells by blocking certain cellular pathways involved in cancer cell proliferation. Combination therapy of temsirolimus and trebananib (AMG 386). Trebananib is an inhibitor of ANG1/2-Tie2 interaction that may inhibit tumor growth by blocking blood flow to tumors. Temsirolimus is an mTOR inhibitor that may stop the growth of tumor cells by blocking the PI3K/Akt/mTOR pathway. The combination was investigated based on evidence of crosstalk between the ANG-Tie2 and PI3K/Akt/mTOR pathways, with the hypothesis that combined blockade may have additive anti-cancer activity.

Other names: trebananib + temsirolimusTr + T

Targets

mTOR (Mammalian target of rapamycin kinase)TEK (Tie2)ANGPT1 (Angiopoietin-1)ANGPT2 (Angiopoietin-2)

Beyond the preview

Go deeper on temsirolimus + trebananib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on temsirolimus + trebananib.

Explore the full profile